Heterogeneous inflammatory patterns in chronic rhinosinusitis without nasal polyps in Chicago, Illinois - 18/04/17
Doi : 10.1016/j.jaci.2016.06.063
Bruce K. Tan, MD, MS a, ∗, Aiko I. Klingler, PhD b, ∗, Julie A. Poposki, MS b, Whitney W. Stevens, MD, PhD b, Anju T. Peters, MD b, Lydia A. Suh, BS b, James Norton, MS b, Roderick G. Carter, BS b, Kathryn E. Hulse, PhD b, Kathleen E. Harris, BS b, Leslie C. Grammer, MD b, Robert P. Schleimer, PhD a, b, Kevin C. Welch, MD a, Stephanie S. Smith, MD a, David B. Conley, MD a, Robert C. Kern, MD a, b, Atsushi Kato, PhD a, b 
a Department of Otolaryngology, Northwestern University Feinberg School of Medicine, Chicago, Ill
b Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Ill
| This research was supported in part by the National Institutes of Health (grant nos. R01 AI104733, U19 AI106683, K23 DC012067, and R37 HL068546) and by a grant from the Ernest S. Bazley Foundation. |
|
| Disclosure of potential conflict of interest: B. K. Tan has received grants from the National Institutes of Health (grant nos. K23 DC012067 and U19 AI106683). A. T. Peters has consultant arrangements with Greer Laboratories. K. E. Hulse has received a grant from the National Institutes of Health. K. E. Harris is employed by Northwestern University. L. C. Grammer has received grants from the National Institutes of Health, the Food Allergy Network, and the Bazley Foundation; has consultant arrangements with Astellas Pharmaceuticals; is employed by Northwestern University and Northwestern Medical Faculty Foundation; has received payment for lectures from the American Academy of Allergy, Asthma, and Immunology and Mount Sinai; has received royalties from Lippincott, UpToDate, BMJ, and Elsevier; and has received travel support from the National Institutes of Health. R. P. Schleimer has received grants from the National Institutes of Health; has consultant arrangements with Intersect ENT, GlaxoSmithKline, Allakos, Aurasense, Merck, BioMarck, Sanofi, AstraZeneca/MedImmune, and Genentech; and has stock/stock options in Allakos, Aurasense, and BioMarck. S. S. Smith has received a grant from the Triological Society Career Development Award and is employed by Northwestern Medicine/Northwestern University. A. Kato has received grants from the National Institutes of Health (grant nos. R01 AI104733 and U19 AI106683) and Janssen Research and has received payment for lectures from Janssen Research. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 139 - N° 2
P. 699 - février 2017 Retour au numéro
Article précédent
- IL-17 enhances the migration of B cells during asthma by inducing CXCL13 chemokine production in structural lung cells
- Roua Al-Kufaidy, Alejandro Vazquez-Tello, Ahmed S. BaHammam, Saleh Al-Muhsen, Qutayba Hamid, Rabih Halwani
- Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect
- Peter D. Sly, Julie Varghese, Farhana Noor, Mimi L.K. Tang, Ingrid Laing, Steve Oo, Franciska Prastanti, Peter N. LeSouef, Patrick G. Holt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?